News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

May 15, 2018

Astellas Appoints Bernhardt Zeiher, M.D., as New Chief Medical Officer

Joins Company's Executive Leadership Team
- Photos 1
May 7, 2018

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms
May 2, 2018

Astellas Included in Forbes Best Midsize Employers List for Fourth Year
Apr 30, 2018

Astellas' Nahrin Marino named a 2018 Healthcare Businesswomen's Association Luminary
- Photos 1
Apr 26, 2018

Astellas Reports Financial Results for FY2017
Apr 23, 2018

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
Apr 18, 2018

Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

Asset Transfer was Completed on April 12, 2018
- Photos 1
Apr 3, 2018

Astellas Named "Outstanding Employer" for Supporting Employees with Military Service
- Photos 1
Mar 28, 2018

Astellas Names Tatjana Dragovic, J.D. Head of Ethics & Compliance

Dragovic was previously Vice President, Ethics & Compliance Americas
- Photos 1
Mar 26, 2018

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 19, 2018

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC
Mar 15, 2018

Astellas Names Percival Barretto-Ko President, Americas Operations

Barretto-Ko was previously Senior Vice President, International Operations
- Photos 1
Mar 13, 2018

Astellas Announces Key Leadership Changes in Legal, Human Resources
- Photos 1
Feb 13, 2018

Astellas Acquires Universal Cells, Inc.

Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas
Feb 5, 2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Jan 31, 2018

Astellas Reports Financial Results for the First Nine Months of FY2017
Jan 29, 2018

Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium

- A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions -
- Photos 1
Jan 23, 2018

Astellas Completes Acquisition of Mitobridge, Inc.
Jan 22, 2018

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
- Photos 1
Jan 8, 2018

Astellas Announces Leadership Changes in Canada and U.S.
- Photos 4
Dec 20, 2017

Astellas to Present at J.P. Morgan Healthcare Conference
Dec 13, 2017

Astellas Appoints Anthony Fiordaliso to Vice President, Americas Finance
- Photos 2
Dec 11, 2017

Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

- Gilteritinib combined with intensive chemotherapy was well-tolerated in newly diagnosed AML patients -
Dec 4, 2017

Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma Brasil
- Photos 1
Nov 30, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

- Accelerating the Discovery and Development of Novel Drugs that Target Mitochondrial Functions -

Show per page